Rejuvenation Biotechnology Update for Q1 2016

The Rejuvenation Biotechnology Update is a collaboration between the Methuselah Foundation and SENS Research Foundation, a newsletter delivered to SENS supporters and members of the Methuselah Foundation 300. The latest edition arrived yesterday, and as usual it is a look at a few of the interesting research results from recent months, with accompanying explanations of their relevance in the bigger picture. The 300 is a group of donors who have supported the Methuselah Foundation for more than a decade now, and the first members stepped up to help get the first initiatives off the ground back when there were only ideas and intents, longevity science was ridiculed, and funding was scarce. Last year a monument was raised to record the names of the 300, the people who have helped bring about a sea change in the aging research community, the philanthropists who funded the M Prize for longevity science, launched the SENS rejuvenation research programs, delivered seed funding to Organovo, and today support the ongoing New Organ Prizes for tissue engineering. If you want to help speed progress towards a world without aging, in which all age-related disease can be prevented and cured, you could do far worse than to become a member of the 300. 2016 Q1 Rejuvenation Biotechnology Update (PDF) Transthyretin deposition in articular cartilage: a novel mechanism in the pathogenesis of osteoarthritis. Transthyretin (TTR) is a protein that normally serves to transport thyroid hormones and...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs